AVXL

Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs.

Robbins LLP announced a class action lawsuit against Anavex Life Sciences Corp. for allegedly misleading investors about inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased AVXL securities between November 26, 2025 and August 28, 2026. The lead plaintiff deadline is November 30, 2026.

Rosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and AST SpaceMobile to join securities class action lawsuits before upcoming deadlines. The lawsuits allege that these companies made false or misleading statements regarding their business operations, internal controls, and regulatory challenges. Investors who purchased securities during specified class periods may be entitled to compensation.